SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 279 filers reported holding SAGE THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $249,335 | -78.0% | 22,959 | -62.1% | 0.01% | -79.5% |
Q1 2024 | $1,135,325 | +5.4% | 60,583 | +21.9% | 0.04% | -4.3% |
Q4 2023 | $1,077,281 | -23.9% | 49,713 | -27.7% | 0.05% | -41.0% |
Q3 2023 | $1,414,978 | +17.2% | 68,755 | +167.7% | 0.08% | +20.0% |
Q2 2023 | $1,207,427 | -7.6% | 25,679 | -17.5% | 0.06% | -19.8% |
Q1 2023 | $1,306,802 | +173.4% | 31,144 | +170.7% | 0.08% | +200.0% |
Q2 2020 | $478,000 | +70.7% | 11,507 | +18.1% | 0.03% | +28.6% |
Q1 2020 | $280,000 | -70.8% | 9,741 | -26.7% | 0.02% | -50.0% |
Q4 2019 | $959,000 | -42.5% | 13,288 | +11.8% | 0.04% | -50.0% |
Q3 2019 | $1,668,000 | -27.7% | 11,887 | -5.7% | 0.08% | -22.9% |
Q2 2019 | $2,307,000 | +3.6% | 12,600 | -10.0% | 0.11% | +1.9% |
Q1 2019 | $2,226,000 | +80.7% | 13,993 | +8.8% | 0.11% | +40.8% |
Q4 2018 | $1,232,000 | -45.4% | 12,866 | -19.4% | 0.08% | -11.6% |
Q3 2018 | $2,255,000 | – | 15,967 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |